Navigation Links
Tethys Bioscience Hits Key Milestones With Series C Funding, Opening of CLIA Laboratory
Date:1/10/2008

Biomarker discovery company builds strong financial and clinical foundation in preparation for release of technology enabling early detection of risk

for diabetes

EMERYVILLE, Calif., Jan. 10 /PRNewswire/ -- Tethys Bioscience today announced that it has reached two significant milestones in its drive to release Tethys Diabetes PreDxTM, a multi-biomarker technology that provides a more complete picture of an individual's future risk of developing diabetes. The company received its latest round of funding (Series C), and also received the licensing of its CLIA Lab by the State of California. Both moves place Tethys Bioscience in a strong position to establish itself as a leader in the emerging field of personalized predictive medicine and to achieve its goal of helping to stem the burgeoning epidemic of chronic, high-burden metabolic disease. Tethys Diabetes PreDxTM will be generally available in the first half of 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070702/AQM026LOGO)

The new round of funding is led by Intel Capital, which was created specifically to invest in innovation and has a strong interest in the emerging field of predictive personalized medicine. This latest financing, a process begun with earlier investments from some of the leading venture capital firms, including Kleiner Perkins Caufield & Byers and MDV-Mohr Davidow Ventures, results in a total of $54 million in financing, to date.

"We're very pleased to receive this round of financing from our investors, and believe it supports our vision to dramatically improve the detection and treatment, and ultimately prevention, of chronic diseases," said Mickey Urdea, CEO of Tethys Bioscience. "It gives us the resources to accelerate our work in this critical field, and to introduce a technology that enables a clinically simple blood test that provides an objective means to identify individuals at highest risk for diabetes. Our test will give medical professionals, and their patients, the opportunity to intervene and modify the risk before irreversible damage occurs.

Tethys Bioscience also announced the licensing of its clinical lab by the State of California. This marks a significant step forward for the company, enabling it to make its testing services available for sale and to offer test results obtained in Tethys' own laboratory, where the technology was also developed.

There is a very large market for early detection technology enabling personalized preventive efforts in diabetes and other chronic diseases. It is estimated that up to 7% of the population, or nearly 21 million people, have diabetes, with more than six million of those currently undiagnosed. Further, the number of individuals at risk for diabetes is estimated to be greater than double the number of those with diabetes. Tethys Diabetes PreDxTM involves a simple to administer blood test, which fits easily into current clinical practice and provides clinically important, personalized risk information -- while matching or outperforming traditional clinical risk scores and measures of glucose dysregulation or insulin resistance. About Tethys BioscienceTethys Bioscience is dedicated to the discovery, development and commercialization of novel biological markers -- biomarkers -- that provide a practical tool to address the growing global healthcare challenge of chronic metabolic diseases such as diabetes. Tethys Bioscience comes to market with a unique combination: management, research, and commercialization teams with extensive experience in diagnostic innovation, strategic alliances with world-class researchers and partners, and a solid financial foundation to help transform the management of chronic diseases with personalized, preventive solutions that aid every constituency: patients, doctors, and the healthcare system as a whole.


'/>"/>
SOURCE MDV-Mohr Davidow Ventures
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
2. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
3. Connecticut Bioscience Achievement Awards Presented at CURE Annual Meeting
4. SuperArray Bioscience Corporation Licenses RNA Interference Patent From The Carnegie Institution
5. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
6. KGI and Smith College Announce Speakers for Women Leadership Forum in Bioscience
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
9. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
10. Anaptys Biosciences Raises Over $33 Million in Series B Financing
11. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the ... series, and attorneys from the firm’s global Life Sciences & Medical Technology Group have ...
(Date:12/8/2016)... ... 08, 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 ... the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) ... Dr. Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital health platform ... by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning ... serve more consumers who are managing chronic conditions or simply want to ...
(Date:12/8/2016)... ... 2016 , ... Coppin Insurance Agency, an insurance and financial planning firm based ... Coral area, is embarking on a charity drive with the goal of providing support ... Chapin Food Bank of Southwest Florida works to provide fresh and nutritious food free ...
(Date:12/7/2016)... ... December 07, 2016 , ... Students attending Envision’s summer ... opportunity to get hands-on experience in an emergency medical simulation, When Care is ... gain invaluable, real-life medical skills that are critical success in a future career ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Calif. , Dec. 8, 2016 IRIDEX Corporation ... to offer newly issued shares of common stock, $0.01 par ... to an underwritten public offering.  The final terms of the ... time of pricing, and there can be no assurance as ... IRIDEX expects to use the net proceeds it will ...
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)... -- The global biosurgery market is expected to grow at ... 2016 to 2021. The market is poised to reach ... in 2016. The market is primarily driven by rising ... and spinal problems, increasing clearance of biosurgery products by ... management. In this report, the biosurgery market ...
Breaking Medicine Technology: